Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice-Reference-Cited by-同舟云学术

Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice

Published:2023-07 Issue: Volume:93 Page:104684
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Ying Zhixiong^ORCID,van Eenige Robin^ORCID,Ge Xiaoke^ORCID,van Marwijk Christy,Lambooij Joost M.,Guigas Bruno^ORCID,Giera Martin,de Boer Jan Freark,Coskun Tamer,Qu Hongchang,Wang Yanan,Boon Mariëtte R.,Rensen Patrick C.N.^ORCID,Kooijman Sander^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference56 articles.

1. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: an 8-year follow-up study;Lu;World J Gastroenterol,2016

2. Prevalence and risk factors of fatty liver in Portuguese adults;Leitão;Eur J Clin Invest,2020

3. 2019 global NAFLD prevalence: a systematic Review and meta-analysis;Le;Clin Gastroenterol Hepatol,2021

4. It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them?;Tarantino;Int J Mol Sci,2021

5. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease;Negi;Metabolism,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cav3.2 deletion attenuates nonalcoholic fatty liver disease in mice;Gene;2024-12

2. Effects of the switch from dulaglutide to tirzepatide on glycemic control, body weight, and fatty liver: a retrospective study;Journal of Diabetes & Metabolic Disorders;2024-07-26

3. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature;International Journal of Molecular Sciences;2024-03-29

4. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes;Diabetes, Obesity and Metabolism;2023-11-21